Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB-500 in mild-to-moderate atopic dermatitis
NCT05487963Phase 2Completed
- Sponsor
- CAGE Bio
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INN-04-01 in atopic dermatitis (AD) (2 arms), sponsored by CAGE Bio. Primary endpoints: Safety and Tolerability at 8 weeks and Effectiveness at 8 weeks. Started Nov 2022; status: completed.
02
Drugs
INN-04-01
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05487963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487963.